F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)
Florbetapir F 18 is an experimental radioactive drug that may allow doctors to image changes in the brain using a PET (Positron Emission Tomography) scanner. The purpose of this study is to evaluate the imaging characteristics of, Florbetapir F 18 (also known as 18F-AV-45) in patients who have previously undergone bleeding in their brains. Florbetapir F 18 binds to amyloid-ß peptide (Aß) that accumulates in the brains of patients with bleeding. These accumulations are called amyloid plaques and when extensive are labeled cerebral amyloid angiopathy (CAA). Florbetapir F 18 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera.
MRI detected microbleeds have been identified as markers of clinically silent hemorrhage from bleeding-prone vessels. Another imaging marker of vessel damage and risk of bleeding is the spot sign (SS). Finally, certain genetic signatures (ApoE genotype) have been shown to be associated with Aß deposition in the brain or predispose patients to higher risks of bleeding. This research study will explore the interactions of these factors and understand the physiology of intracerebral bleeding.
研究概览
地位
条件
研究类型
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Prior intracranial hemorrhage at least 3 months prior
- Patients >18 years
Exclusion Criteria:
- Modified Rankin score >3.
- Clinically significant medical comorbidities which in the opinion of the investigator might pose a potential safety risk to the subject.
- Women of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.
- Have a history of relevant severe drug allergy or hypersensitivity
- Patients who withdraw consent. Age and gender-matched microbleed patients previously demonstrating MRI microbleeds without prior macrobleeds will be recruited from stroke clinic
学习计划
研究是如何设计的?
设计细节
- 观测模型:病例对照
- 时间观点:预期
队列和干预
团体/队列 |
|---|
|
CAA positive microbleeders
Cerebral amyloid angiopathy (CAA) positive microbleeders
|
|
probable CAA macrobleeders
|
|
CAA negative microbleeders
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Type of Bleed
大体时间:2-3 weeks
|
Patients will be divided into micro- and macro- bleeders based on MRI detected microhemorhage pattern.
Processing of each patient will take 2-3 weeks.
|
2-3 weeks
|
|
Spot Sign Status
大体时间:2-3 weeks
|
They will be further subdivided by spot sign status into positive or negative.
|
2-3 weeks
|
|
Amyloid uptake
大体时间:2-3 weeks
|
2-3 weeks
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
ApoE genotype
大体时间:2-3 weeks
|
2-3 weeks
|
合作者和调查者
调查人员
- 首席研究员:Richard Aviv、Sunnybrook Health Sciences Centre
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.